226 related articles for article (PubMed ID: 23014069)
1. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years.
Molinaro E; Pieruzzi L; Viola D
J Endocrinol Invest; 2012; 35(6 Suppl):16-20. PubMed ID: 23014069
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
5. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer.
Luster M; Hänscheid H; Freudenberg LS; Verburg FA
J Endocrinol Invest; 2012; 35(6 Suppl):21-9. PubMed ID: 23014070
[TBL] [Abstract][Full Text] [Related]
8. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
[TBL] [Abstract][Full Text] [Related]
9. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when.
Barbaro D; Boni G
Eur J Surg Oncol; 2007 Jun; 33(5):535-40. PubMed ID: 17337154
[TBL] [Abstract][Full Text] [Related]
11. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine ablation: when and how.
Ambrosetti MC; Colato C; Dardano A; Monzani F; Ferdeghini M
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):473-81. PubMed ID: 19910900
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
Pacini F; Castagna MG
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
[TBL] [Abstract][Full Text] [Related]
16. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
17. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
18. [Radiometabolic therapy for metastatic thyroid carcinoma: overview of the literature and rational bases for the use of recombinant human TSH].
Testori O; Bagnasco M; Banti E; Bombardieri E; Dottorini ME; Fugazzola L; Maffioli L; Perotti G; Rubello D; Seregni E
Minerva Med; 2012 Jun; 103(3):209-18. PubMed ID: 22653101
[TBL] [Abstract][Full Text] [Related]
19. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures.
Reiners C; Dietlein M; Luster M
Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):989-1007. PubMed ID: 19041827
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
Fu H; Ma C; Tang L; Wu F; Liu B; Wang H
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
